Inhibin-betaA and -betaB subunits in normal and malignant glandular epithelium of uterine cervix and HeLa cervical cancer cell line

Archives of Gynecology and Obstetrics

Volumn 284, Issue 4, 2011, Pages 981-988

  Burges, Alexander ^a   Shabani, Naim ^b,c   Brüning, Ansgar ^a,c   Mylonas, Ioannis ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Klinikum Neuperlach   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adenocarcinoma; Cervical cancer; Cervical cancer cell line; Hela; Immunofluorescence; Immunohistochemistry; Inhibin betaA; Inhibin betaB; RT PCR

Indexed keywords

INHIBIN; INHIBIN BETAA; INHIBIN BETAB; MESSENGER RNA; UNCLASSIFIED DRUG; INHBB PROTEIN, HUMAN; INHIBIN BETA A SUBUNIT; PRIMER DNA;

ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION REGULATION; HELA CELL; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INHIBIN BETAA GENE; INHIBIN BETAB GENE; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; UTERINE CERVIX; UTERINE CERVIX TUMOR;

CERVIX UTERI; DNA PRIMERS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; INHIBIN-BETA SUBUNITS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 84856251048     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1734-4     Document Type: Article

References (51)

1. Franco EL, Schlecht NF, Saslow D (2003) The epidemiology of cervical cancer. Cancer J 9:348-359 (Pubitemid 44403488)
2. Waggoner SE (2003) Cervical cancer. Lancet 361:2217-2225. doi:10.1016/S0140-6736(03)13778-6 (Pubitemid 36782559)
3. Gien LT, Beauchemin MC, Thomas G (2010) Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 116:140-146. doi: 10.1016/j.ygyno.2009.09.040
4. Wang X, Liu R, Ma B, Yang K, Tian J, Jiang L, Bai ZG, Hao XY, Wang J, Li J, Sun SL, Yin H (2010) High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 7:CD007563. doi: 10.1002/14651858.CD007563.pub2
5. Wang N, Guan QL, Wang K, Zhou X, Gao C, Yang HT, Ni TG (2010) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet. doi:10.1007/s00404-010-1385-56
6. Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-560. doi:10.1038/nrc2886
7. Barthell E, Woelber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings HL, Railkar R, Gause C, Barr E (2009) Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Arch Gynecol Obstet 279:803-807. doi:10.1007/s00404-008-0806-1
8. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527. doi:10.1056/NEJMoa 0216413 (Pubitemid 36159887)
9. zur Hausen H (2009) Papillomaviruses in the causation of human cancers-a brief historical account. Virology 384:260-265. doi: 10.1016/j.virol.2008.11.046
10. Han CP, Kok LF, Lee MY, Wu TS, Ruan A, Cheng YW, Wang PH, Koo CL, Tyan YS (2010) Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. Arch Gynecol Obstet 281:317-323. doi:10.1007/s00404-009-1115-z
11. Yao CC, Kok LF, Lee MY, Wang PH, Wu TS, Tyan YS, Cheng YW, Kung MF, Han CP (2009) Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet 280:405-413. doi:10.1007/s00404-008-0859-1
12. Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S (2004) Activins and inhibins and their signaling. Ann N Y Acad Sci 1038:142-147 (Pubitemid 40577455)
13. Xia Y, Schneyer AL (2009) The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202:1-12. doi:10.1677/JOE-08- 0549
14. Bergauer F, Bruning A, Shabani N, Blankenstein T, Juckstock J, Dian D, Mylonas I (2009) Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines. J Mol Histol 40:353-359. doi:10.1007/s10735-009-9246-x
15. Kimmich T, Bruning A, Kaufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K, Mylonas I (2010) Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet 282:185-191. doi:10.1007/s00404-009-1310-y
16. Kaufl SD, Kuhn C, Kunze S, Shabani N, Bruning A, Friese K, Mylonas I (2010) Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer. Arch Gynecol Obstet doi:10.1007/s00404-010-1614-y
17. Gingelmaier A, Bruning A, Kimmich T, Makovitzky J, Bergauer F, Schiessl B, Friese K, Mylonas I (2010) Inhibin/activin-betaE subunit is expressed in normal and pathological human placental tissue including chorionic carcinoma cell lines. Arch Gynecol Obstet doi:10.1007/s00404-009-1340-5
18. Weissenbacher T, Bruning A, Kimmich T, Makovitzky J, Gingelmaier A, Mylonas I (2010) Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J Histochem Cytochem 58:751-757. doi:10.1369/jhc.2010.956185
19. Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocr Rev 22:836-858 (Pubitemid 34214298)
20. Mylonas I, Shabani N, Vogl J, Makovitzky J, Kunze S, Kuhn C, Schulze S, Friese K, Jeschke U (2007) Inhibin/activin subunits are immunohistochemically expressed in complete and partial hydatidiform moles. Anticancer Res 27:1995-2000 (Pubitemid 46954714)
21. Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Kunze S, Schulze S, Kainer F, Friese K (2006) Expression of inhibin/activin subunits alpha (-alpha), beta A (- beta (A)) and beta B (-beta (B)) in placental tissue of normal and intrauterine growth restricted (IUGR) pregnancies. J Mol Histol 37:43-52 (Pubitemid 44421092)
22. Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Schulze S, Kainer F, Friese K (2006) Expression of inhibin/activin subunits alpha (-alpha), betaA (-betaA), and betaB (-betaB) in placental tissue of normal, preeclamptic and HELLP pregnancies. Endocr Pathol 17:19-34
23. Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V, Friese K (2003) Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. Arch Gynecol Obstet 268:142-150. doi:10.1007/s00404-003-0526-5 (Pubitemid 36988445)
24. Mylonas I, Makovitzky J, Fernow A, Richter DU, Jeschke U, Briese V, Gerber B, Friese K (2005) Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps. Arch Gynecol Obstet 272:59-66. doi:10.1007/s00404- 004-0666-2 (Pubitemid 40896637)
25. Worbs S, Shabani N, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K, Mylonas I (2007) Expression of the inhibin/activin subunits (-alpha, -betaA and - betaB) in normal and carcinogenic endometrial tissue: Possible immunohistochemical differentiation markers. Oncol Rep 17: 97-104
26. Mylonas I (2010) Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: Prognostic significance and clinical implications. Eur J Cancer 46:2485-2493. doi:10. 1016/j.ejca.2010.06.001
27. Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Vigano P, Di Blasio AM, Genazzani AR, Vale W (1998) Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 83: 1194-1200 (Pubitemid 28496392)
28. Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS, Friese K (2004) Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122:461-471 (Pubitemid 40379015)
29. Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45:1304-1314. doi:10.1016/j.ejca.2009. 01.008
30. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V, Friese K (2004) Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 93:92-97 (Pubitemid 38429554)
31. Otani T, Minami S, Kokawa K, Shikone T, Yamoto M, Nakano R (1998) Immunohistochemical localization of activin A in human endometrial tissues during the menstrual cycle and in early pregnancy. Obstet Gynecol 91:685-692 (Pubitemid 28208856)
32. Gingelmaier A, Gutsche S, Mylonas I, Shabani N, Kuhn C, Kunze S, Jeschke U, Friese K (2007) Expression of HPV, steroid receptors (ERalpha, ERbeta, PR-A and PR-B) and inhibin/activin subunits (alpha, betaA and betaB) in adenosquamous endometrial carcinoma. Anticancer Res 27:2011-2017 (Pubitemid 46954717)
33. Jückstock K, Brüning A, Blankenstein T, Kunze S, Shaban N, Bergauer F, Mylonas I (2010) Immunolabeling of the inhibinbetaA and -betaB subunit in normal and malignant human cervical tissue and cervical cancer cell line. Int J Gynecol Cancer 20:1177-1125
34. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K (2009) Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 7:15. doi: 10.1186/1478-811X-7-15
35. Blankenstein TJF, Jückstock JK, Shabani N, Kunze S, Brüning A, Bergauer F, Mylonas I (2010) Immunolabelling of the inhibin/activin-betaC subunit in normal and malignant human uterine cervical tissue and cervical cancer cell lines. Oncol Rep (in press)
36. Bruning A, Makovitzky J, Gingelmaier A, Friese K, Mylonas I (2009) The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol 132:33-38. doi:10.1007/s00418- 009-0595-z
37. Mylonas I (2010) Inhibin-betaA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation? Arch Gynecol Obstet doi:10.1007/s00404-010- 1680-1
38. Risbridger GP, Ball EM, Wang H, Mellor SL, Peehl DM (2004) Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol Cell Endocrinol 225:73-76 (Pubitemid 39297056)
39. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, Ogata E, Miyazono K, Shimizu K, Imamura T (2007) Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98:127-133 (Pubitemid 44803931)
40. Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S (2008) Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer celldepleted SCID mice. Clin Cancer Res 14:660-667 (Pubitemid 351231145)
41. Farley J, Gray K, Nycum L, Prentice M, Birrer MJ, Jakowlew SB (2000) Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27(Kip1). Gynecol Oncol 78: 113-122 (Pubitemid 30650340)
42. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A (1992) Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313-319 (Pubitemid 23000668)
43. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A (1994) Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91:8817-8821
44. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M (2003) Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 112:575-587 (Pubitemid 38056342)
45. Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, Bartholin L, Rimokh R (2007) Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res 67:7223-7229 (Pubitemid 47206550)
46. Ramachandran A, Marshall ES, Love DR, Baguley BC, Shelling AN (2009) Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett 285:157-165. doi:10.1016/j.canlet.2009.05.010
47. Katik I, Mackenzie-Kludas C, Nicholls C, Jiang FX, Zhou S, Li H, Liu JP (2009) Activin inhibits telomerase activity in cancer. Biochem Biophys Res Commun 389:668-672. doi:10.1016/j.bbrc.2009.09.055
48. Di Simone N, Crowley WF Jr, Wang QF, Sluss PM, Schneyer AL (1996) Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137:486-494 (Pubitemid 26049884)
49. Di Simone N, Hall HA, Welt C, Schneyer AL (1998) Activin regulates betaA-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells. Endocrinology 139:1147-1155 (Pubitemid 28510134)
50. Di Simone N, Schneyer AL, Caliandro D, Castellani R, Caruso A (2002) Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol 192:187-195 (Pubitemid 34667236)
51. Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF (2005) Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 3:50-61 (Pubitemid 40189596)